SCHEMBL266014

SCHEMBL266014

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2ccc(OC)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
KDM4E B2RXH2 5/20 0.49
HPGD P15428 4/20 0.49
ALDH1A1 P00352 4/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SLC34A2 O95436 3/20 0.47
SLC34A1 Q06495 1/20 0.47
SLC34A3 Q8N130 1/20 0.47
SLC20A1 Q8WUM9 1/20 0.47
F10 P00742 5/20 0.45
F2 P00734 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
PKM P14618 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
ALOX12 P18054 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266015 1.00 MAPT (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL268018 0.94 KDM4E (0.51) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL268019 0.94 KDM4E (0.51) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL268366 0.93 SLC34A2 (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL268365 0.93 SLC34A2 (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL269408 0.92 SLC34A2 (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL269407 0.92 SLC34A2 (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL267150 0.92 KDM4E (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL267149 0.92 KDM4E (0.49) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL268277 0.92 SLC34A2 (0.48) MAPTHPGDALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885KDM4E 4468/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885KDM4E 4535/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.